These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 3119815)

  • 1. Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin.
    Nakashima E; Noonan PK; Benet LZ
    J Pharmacokinet Biopharm; 1987 Aug; 15(4):423-37. PubMed ID: 3119815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism.
    Wester RC; Noonan PK; Smeach S; Kosobud L
    J Pharm Sci; 1983 Jul; 72(7):745-8. PubMed ID: 6411893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations.
    Williams RL; Thakker KM; John V; Lin ET; Liang-Gee W; Benet LZ
    Pharm Res; 1991 Jun; 8(6):744-9. PubMed ID: 1905809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of skin site on bioavailability of nitroglycerin ointment in congestive heart failure.
    Moe G; Armstrong PW
    Am J Med; 1986 Nov; 81(5):765-70. PubMed ID: 3096133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique.
    Sun JX; Piraino AJ; Morgan JM; Joshi JC; Cipriano A; Chan K; Redalieu E
    J Clin Pharmacol; 1995 Apr; 35(4):390-7. PubMed ID: 7650229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of a new transdermal nitroglycerin adhesive patch formulation.
    Riedel DJ; Wick KA; Hawkinson RW; Kolars CA; Crowley JK; Armstrong KE; Chang SF; Harrison LI; de Dennis SR
    Clin Ther; 1989; 11(2):225-31. PubMed ID: 2500248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel pharmacokinetic modelling of transdermal nitroglycerin.
    Auclair B; Sirois G; Ngoc AH; Ducharme MP
    Pharm Res; 1998 Apr; 15(4):614-9. PubMed ID: 9587959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-hemodynamic studies of transdermal nitroglycerin in congestive heart failure.
    Armstrong PW
    J Am Coll Cardiol; 1987 Feb; 9(2):420-5. PubMed ID: 3100600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitroglycerin concentration in plasma: comparison between transdermal therapeutic system and ointment.
    Chu LC; Gale RM; Schmitt LG; Shaw JE
    Angiology; 1984 Sep; 35(9):545-52. PubMed ID: 6435484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical pharmacology of nitroglycerin for controlled transdermal administration].
    Rewerski W; Janicki PK
    Pol Arch Med Wewn; 1988; 80(2-3):151-5. PubMed ID: 3152129
    [No Abstract]   [Full Text] [Related]  

  • 11. Dose proportionality of transdermal nitroglycerin.
    Jewell RC; Banfield CR; Ruggirello DA; Huang YW; Noonan PK; Gonzalez MA
    Pharm Res; 1992 Oct; 9(10):1284-9. PubMed ID: 1448427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethanol: water mutually enhanced transdermal therapeutic system II: skin permeation of ethanol and nitroglycerin.
    Berner B; Mazzenga GC; Otte JH; Steffens RJ; Juang RH; Ebert CD
    J Pharm Sci; 1989 May; 78(5):402-7. PubMed ID: 2501473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system.
    Auclair B; Sirois G; Ngoc AH; Ducharme MP
    Ther Drug Monit; 1998 Dec; 20(6):607-11. PubMed ID: 9853974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous absorption of 1,3-dinitroglycerin and a trial of pharmacokinetic analysis.
    Ogiso T; Iwaki M; Kanokogi A; Terao Y
    Chem Pharm Bull (Tokyo); 1990 Oct; 38(10):2829-33. PubMed ID: 2127557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical considerations of transdermal nitroglycerin delivery: the various approaches.
    Chien YW
    Am Heart J; 1984 Jul; 108(1):207-16. PubMed ID: 6428207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal absorption of nitroglycerin from microseal drug delivery (MDD) system.
    Karim A
    Angiology; 1983 Jan; 34(1):11-22. PubMed ID: 6401951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitroglycerin levels after administration via transdermal therapeutic system or nitroglycerin ointment.
    Taylor SH
    Lancet; 1984 Jul; 2(8394):97. PubMed ID: 6146027
    [No Abstract]   [Full Text] [Related]  

  • 18. Nitroglycerin levels after administration via transdermal therapeutic system or nitroglycerin ointment.
    Curry SH; Kwon HR; Perrin JH; Culp JR; Pepine CJ; Yu W
    Lancet; 1984 Jun; 1(8389):1297. PubMed ID: 6145002
    [No Abstract]   [Full Text] [Related]  

  • 19. Percutaneous penetration kinetics of nitroglycerin and its dinitrate metabolites across hairless mouse skin in vitro.
    Kikkoji T; Gumbleton M; Higo N; Guy RH; Benet LZ
    Pharm Res; 1991 Oct; 8(10):1231-7. PubMed ID: 1796039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous metabolism of nitroglycerin in vitro. I. Homogenized versus intact skin.
    Higo N; Hinz RS; Lau DT; Benet LZ; Guy RH
    Pharm Res; 1992 Feb; 9(2):187-90. PubMed ID: 1553339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.